MedTrace Logo

Topical Sulfasalazine and Oral Lichen Planus

NCT06060301 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-08-01

No results posted yet for this study

Summary

Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal membrane. T-cell mediated damage against the mucosal epithelial cells is implicated in the pathogenesis of OLP, although the exact mechanism is unknown.

Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. In spite of its effectiveness, the anti-inflammatory mechanism is not clearly understood.

Conditions

Interventions

DRUG

sulfasalazine 500 MG

The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.

DRUG

corticosteroids

The patients will use topical corticosteroids 4 times per day.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Faculty O Dentistry, Cairo University · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-09-01
Completion
2024-10-20

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06060301 on ClinicalTrials.gov